A novel CXCL8-IP10 hybrid protein is effective in blocking pulmonary pathology in a mouse model of Klebsiella pneumoniae infection
| Autor: | Fang Li, Zhangbo Chen, Hui-Yuan Yu, Xiangyu Chen, Jya-Wei Cheng, Shu-Chi Yeh, Hsi-Tsung Cheng |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
musculoskeletal diseases
0301 basic medicine medicine.medical_specialty Chemokine Neutrophils Klebsiella pneumoniae Recombinant Fusion Proteins Immunology Ceftazidime Microbiology 03 medical and health sciences Pneumonia Bacterial medicine Animals Immunology and Allergy Interleukin 8 Pulmonary pathology Dexamethasone Pharmacology biology business.industry Interleukin-8 Chemotaxis medicine.disease biology.organism_classification Klebsiella Infections Chemokine CXCL10 Mice Inbred C57BL Chemotaxis Leukocyte Disease Models Animal 030104 developmental biology biology.protein Female Histopathology business medicine.drug |
| Zdroj: | International Immunopharmacology. 62:40-45 |
| ISSN: | 1567-5769 |
| DOI: | 10.1016/j.intimp.2018.06.040 |
| Popis: | Klebsiella pneumoniae (K. pneumoniae) is a hospital-acquired infectious agent that causes a range of diseases. Herein we have developed a novel CXCL8-IP10 hybrid protein and evaluated its efficacy in an animal model of K. pneumoniae infection. Neutrophil chemotaxis data revealed that CXCL8-IP10 could inhibit human neutrophil chemotactic responses induced by the ELR-CXC chemokine CXCL8. To evaluate the effect of CXCL8-IP10 on K. pneumoniae infection, C57BL/6 mice were challenged with K. pneumoniae followed by treatment with CXCL8-IP10 (500 μg/kg, i.p.), or dexamethasone (0.8 mg/kg, s.c.), or ceftazidime (200 mg/kg, s.c.) individually. CXCL8-IP10, dexamethasone or ceftazidime markedly inhibit Klebsiella-induced pulmonary inflammation as assessed by gross examination and histopathology. Moreover, the chemotactic responses of neutrophils was blocked by CXCL8-IP10 rather than dexamethasone or ceftazidime. Furthermore, the levels of inflammatory factors IL-1β, IFN-γ and TNF-α were decreased after CXCL8-IP10, dexamethasone or ceftazidime treatment. Together, these results suggest that CXCL8-IP10 may provide a novel strategy for treating K. pneumoniae infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect